品牌名称：

型号规格：

批准文号： 非器械产品

产品标签：维生素D结合蛋白

产品卖点：新产品

销售渠道：医院

025-86978335

产品介绍：

【产品名称】

通用名称：阿狄科®维生素D结合蛋白试剂盒（酶联免疫法）

英文名称：Vitamin D Binding Protein (VDBP) ELISA

【包装规格】

96人份/盒

【预期用途】

本产品用于定量测定血清、血浆和尿液中游离的和非肌动复合物结合的维生素D结合蛋白(VDBP)。仅供科研使用。仅用于体外诊断。

【背景知识】

维生素D结合蛋白（VDBP，也称为组特异性组分/Gc蛋白）是在肝脏中形成的一种多功能血清蛋白。由怀孕或激素避孕引起的高雌激素水平会刺激其合成。VDBP可在血浆、腹水、液体、尿液以及各种类型的细胞表面发现。 在血液中，VDBP与循环中的大部分25-OH维生素D结合，并将其带入肾脏，在肾脏中转化为1,25-(OH)2维生素D激素。 此外，VDBP以1:1的比例与单分子肌动蛋白结合。肌动蛋白是一种细胞内蛋白质，可以作为单体或单丝。大量组织破坏或细胞死亡导致肌动蛋白的血浆水平显著升高，从而形成VDBP肌动蛋白复合物，并迅速被清除。因此，创伤或脓毒症患者的VDBP水平迅速下降，特别是多器官功能衰竭水平高的患者。 此外，VDBP是免疫调节蛋白Gc-MAF（Gc蛋白衍生的巨噬细胞活化因子）的前体，它增加了巨噬细胞抗肿瘤的活性。

样本要求：血清、血浆和尿液样本

储存条件：本产品在2-8℃下保存，可稳定至标签所示日期。

参考文献：

1. Bouillon, R., van Baelen, H. & de Moor, P., 1977. The measurement of the vitamin D-binding protein in human serum. The Journal of clinical endocrinology and metabolism, 45(2), pp.225–31.

2. Fu, L. et al., 2009. Common genetic variants of the vitamin D binding protein (DBP) predict differences in response of serum 25-hydroxyvitamin D [25(OH)D] to vitamin D supplementation. Clinical biochemistry, 42(10-11), pp.1174–7.

3. Haughton, M.A. & Mason, R.S., 1992. Immunonephelometric assay of vitamin Dbinding protein. Clinical chemistry, 38(9), pp.1796–801.

4. Heijboer, A.C. et al., 2012. Accuracy of 6 Routine 25-Hydroxyvitamin D Assays: Influence of Vitamin D Binding Protein Concentration. Clinical Chemistry, 58(3), pp.543–548.

5. Jørgensen, C.S. et al., 2004. Gc globulin (vitamin D-binding protein) levels: an inhibition ELISA assay for determination of the total concentration of Gc globulin in plasma and serum. Scandinavian journal of clinical and laboratory investigation, 64(2), pp.157–66.

6. Malik, S. et al., 2013. Common variants of the vitamin D binding protein gene and adverse health outcomes. Critical reviews in clinical laboratory sciences.

7. Schmidt-Gayk, H. et al., 1977. 25-hydroxy-vitamin-D in nephrotic syndrome. Lancet, 2(8029), pp.105–8.

8. Thomas, L., 1982. Proteindiagnostik: Diagnose, Therapiekontrolle. 1st ed., Frankfurt am Main: Behringwerke, Medizinische Information und Vertrieb.

9. Cauley, J.A. et al., 2011. Serum 25-hydroxyvitamin D and clinical fracture risk in a multiethnic cohort of women: the Women’s Health Initiative (WHI). Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 26(10), pp.2378–88.

10. Comabella, M. et al., 2010. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain : a journal of neurology, 133(Pt 4), pp.1082–93.

11. Correale, J., Ysrraelit, M.C. & Gaitán, M.I., 2010. Gender differences in 1,25 dihydroxyvitamin D3 immunomodulatory effects in multiple sclerosis patients and healthy subjects. Journal of immunology (Baltimore, Md. : 1950), 185(8), pp.4948– 58.

12. Doorenbos, C.R.C. et al., 2012. Antiproteinuric treatment reduces urinary loss of vitamin D-binding protein but does not affect vitamin D status in patients with chronic kidney disease. The Journal of steroid biochemistry and molecular biology, 128(1-2), pp.56–61.

13. Gressner, O. et al., 2007. Gc-globulin concentrations and C5 haplotype-tagging polymorphisms contribute to variations in serum activity of complement factor C5. Clinical biochemistry, 40(11), pp.771–5.

14.Jeffery, L.E. et al., 2012. Availability of 25-hydroxyvitamin D(3) to APCs controls the balance between regulatory and inflammatory T cell responses. Journal of immunology (Baltimore, Md. : 1950), 189(11), pp.5155–64.

15.Jeng, L. et al., 2009. Alterations in vitamin D status and anti-microbial peptide levels in patients in the intensive care unit with sepsis. Journal of translational medicine, 7, p.28.

16. Lee, S.-H. et al., 2011. Relationship between group-specific component protein and the development of asthma. American journal of respiratory and critical care medicine, 184(5), pp.528–36.

17. Meguro, S. et al., 2011. Plasma 25-hydroxyvitamin d is independently associated with hemoglobin concentration in male subjects with type 2 diabetes mellitus. International journal of endocrinology, 2011, p.362981.

18. Mirković, K. et al., 2013. Urinary vitamin D binding protein: a potential novel marker of renal interstitial inflammation and fibrosis. PloS one, 8(2), p.e55887.

19. Prytuła, A. et al., 2012. Urinary and dialysate losses of vitamin D-binding protein in children on chronic peritoneal dialysis. Pediatric nephrology (Berlin, Germany), 27(4), pp.643–9. 20. Turner, A.M. et al., 2013. Circulating DBP level and prognosis in operated lung cancer: an exploration of pathophysiology. The European respiratory journal, 41(2), pp.410–6.

21. Wagner, D. et al., 2013. Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and ki67 labeling in prostate cancer patients. The Journal of clinical endocrinology and metabolism, 98(4), pp.1498–507.

22. Wang, X. et al., 2013. Vitamin D-binding protein levels in female patients with primary hyperparathyroidism. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 19(4), pp.609–13.

23. Wood, A.M. et al., 2011. Vitamin D-binding protein contributes to COPD by activation of alveolar macrophages. Thorax, 66(3), pp.205–10.

• 蛋白质电泳仪
• 蛋白水凝胶敷料
• 蛋白创面液体敷料
• 蛋白阴道凝胶敷料
• 维生素检测仪
• 蛋白鼻腔液体敷料
• 蛋白分析仪